D Crook1, I F Godsland, J Hull, J C Stevenson. 1. Wynn Division of Metabolic Medicine, Imperial College School of Medicine, National Heart and Lung Institute, London.
Abstract
OBJECTIVE: To assess serum lipid and lipoprotein concentrations and oral glucose tolerance in postmenopausal women treated with 17 beta-oestradiol (2 mg/day) and cyclical dydrogesterone (10 mg/day for 14 days per 28 day cycle). DESIGN: A 24 month prospective study of 29 women acting as their own controls. On-treatment samples were taken during the combined (oestrogen-progestogen) phase of therapy. SETTING: Metabolic research unit in London. POPULATION: Postmenopausal women with no previous exposure to hormone replacement therapy attending a menopause clinic in a London hospital. METHODS: Fasting serum sampling and oral glucose tolerance testing. MAIN OUTCOME MEASURES: Serum lipids and lipoprotein concentrations and plasma glucose, insulin and C-peptide responses to an oral glucose load. RESULTS: Restricting the analysis to the 17 women who completed the study, no effect was seen on serum triglyceride concentrations. There was a mean fall of 5.9% (95% CI 1.2 to -13.0) in concentrations of serum total cholesterol, reflecting the balance of a 10.7% fall (95% CI 4.3 to -25.8) in low density lipoprotein cholesterol concentrations and a 16.3% increase (95% CI 7.3 to -25.3) in those of high density lipoproteins. Fasting glucose concentrations and glucose tolerance test responses were unchanged. Fasting insulin concentrations fell substantially (-41.6%, 95% CI -23.4 to -59.8) with falls also being seen in insulin responses to glucose. Fasting C-peptide concentrations increased by 36.2% (95% CI 9.17 to 63.3), with no consistent effect on C-peptide responses to glucose. CONCLUSIONS: Dydrogesterone did not appear to oppose the potentially beneficial effects of oestradiol on insulin or either low or high density lipoproteins, making the combination with 17 beta-oestradiol a potentially useful option for postmenopausal women particularly those at risk of cardiovascular disease or diabetes mellitus.
OBJECTIVE: To assess serum lipid and lipoprotein concentrations and oral glucose tolerance in postmenopausal women treated with 17 beta-oestradiol (2 mg/day) and cyclical dydrogesterone (10 mg/day for 14 days per 28 day cycle). DESIGN: A 24 month prospective study of 29 women acting as their own controls. On-treatment samples were taken during the combined (oestrogen-progestogen) phase of therapy. SETTING: Metabolic research unit in London. POPULATION: Postmenopausal women with no previous exposure to hormone replacement therapy attending a menopause clinic in a London hospital. METHODS: Fasting serum sampling and oral glucose tolerance testing. MAIN OUTCOME MEASURES: Serum lipids and lipoprotein concentrations and plasma glucose, insulin and C-peptide responses to an oral glucose load. RESULTS: Restricting the analysis to the 17 women who completed the study, no effect was seen on serum triglyceride concentrations. There was a mean fall of 5.9% (95% CI 1.2 to -13.0) in concentrations of serum total cholesterol, reflecting the balance of a 10.7% fall (95% CI 4.3 to -25.8) in low density lipoprotein cholesterol concentrations and a 16.3% increase (95% CI 7.3 to -25.3) in those of high density lipoproteins. Fasting glucose concentrations and glucose tolerance test responses were unchanged. Fasting insulin concentrations fell substantially (-41.6%, 95% CI -23.4 to -59.8) with falls also being seen in insulin responses to glucose. Fasting C-peptide concentrations increased by 36.2% (95% CI 9.17 to 63.3), with no consistent effect on C-peptide responses to glucose. CONCLUSIONS:Dydrogesterone did not appear to oppose the potentially beneficial effects of oestradiol on insulin or either low or high density lipoproteins, making the combination with 17 beta-oestradiol a potentially useful option for postmenopausal women particularly those at risk of cardiovascular disease or diabetes mellitus.
Authors: B de Lauzon-Guillain; A Fournier; A Fabre; N Simon; S Mesrine; M-C Boutron-Ruault; B Balkau; F Clavel-Chapelon Journal: Diabetologia Date: 2009-07-23 Impact factor: 10.122
Authors: K L Margolis; D E Bonds; R J Rodabough; L Tinker; L S Phillips; C Allen; T Bassford; G Burke; J Torrens; B V Howard Journal: Diabetologia Date: 2004-07-14 Impact factor: 10.122
Authors: Ekta Kapoor; Juliana M Kling; Angie S Lobo; Stephanie S Faubion Journal: Best Pract Res Clin Endocrinol Metab Date: 2021-09-10 Impact factor: 4.690